spacer
home > ict > autumn 2020 > accelerating processes and enhancing compliance with pharmacovigilance automation
PUBLICATIONS
International Clinical Trials

Accelerating Processes and Enhancing Compliance with Pharmacovigilance Automation

Adverse event (AE) information comes from healthcare professionals, manufacturers, and patients themselves, producing a huge volume of data to analyse. Life science organisations face a daily challenge capturing this information, assessing its significance, and reporting it to the authorities in a timely manner, so that safety information can be updated and, if appropriate, additional action can be taken.

It is clear that pharmaceutical companies should be harnessing the latest technology to capture and process the workloads. The range of technology options are considerable, and the technology is proven, reliable, and highly cost-efficient. However, it does appear that companies could be doing so much more with technology.

Many pharma companies believe they are making good use of technology for AE data capture and reporting, according to a recent survey. The research examines life science companies’ attitudes towards, and plans for, pharmacovigilance (PV) automation, particularly

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr John Price, owner and Managing Director of John Price PharmaSolutions LLC, is a life science regulatory and safety veteran and consultant, and an advisor to PV managed service provider Arriello.

drjsprice@pharmacovigilantes.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. 17.7 months with bevacizumab alone One in two women with advanced ovarian cancer has an HRD-positive tumour
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement